Yes, targeting ER stress pathways is a promising therapeutic strategy. Small molecules that modulate the UPR can potentially alleviate ER stress and improve cellular function. For example, chemical chaperones like 4-Phenylbutyric Acid (4-PBA) and Tauroursodeoxycholic Acid (TUDCA) can enhance protein folding and reduce ER stress, offering potential benefits in diseases such as diabetes and neurodegenerative disorders.
